Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Antispasmodics Drugs Industry?

The market for antispasmodics drugs has seen robust growth in recent years. The sector is expected to expand from a value of $13.76 billion in 2024 to $14.93 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.5%. Growth during the historic period can be traced back to factors such as an increase in spasmodic conditions, advancements in medical research, old age population growth, shifting lifestyles, and enhancements in diagnostic procedures.

It is predicted that the market for antispasmodic drugs will witness robust growth in the upcoming years, expanding to “$21.44 billion by 2029, with a compound annual growth rate (CAGR) of 9.5%. This growth within the forecasted period can be linked to factors such as heightened healthcare spending, custom-made medicine, an upsurge in global population, emergence of new markets, clinical research, and trials. Key trends to look out for during this forecast period include broadening usage of antispasmodics, development of healthcare infrastructure, progress in drug improvement, heightened awareness and diagnoses, and preference for non-intrusive treatment alternatives.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9414&type=smp

#Which Factors Are Currently Driving The Growth Of The Antispasmodics Drugs Market?

The projected rise in the elderly population is anticipated to fuel the expansion of the antispasmodic drug market. Individuals who are 65 years old and above, categorized as elderly, often grapple with numerous physical and mental health challenges. Antispasmodic medications are beneficial for the elderly as they ease symptoms linked to multiple conditions causing muscle spasms or cramps, and can also be used to manage conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. For example, in October 2022, the World Health Organization (WHO), an organization based in Switzerland that stands responsible for global public health, stated that the global ratio of individuals aged 60 and above is predicted to escalate to 1.4 billion by 2030. Additionally, the global count of individuals aged 60 or over is set to double by 2050, reaching 2.1 billion. Furthermore, the population of people aged 80 and above is anticipated to see a significant surge by 2050, touching 426 million. Consequently, the increasing elderly population is expected to stimulate the growth of the antispasmodic drug market.

How Is The Global Antispasmodics Drugs Market Structured In Terms Of Segments?

The antispasmodics drugs market covered in this report is segmented –

1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs

2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Dicyclomine Hydrochloride: Oral Tablets, Injectable Formulations

2) By Loperamide Hydrochloride: Oral Tablets, Liquid Formulations

3) By Other Drugs: Hyoscine Butylbromide (Scopolamine), Peppermint Oil, Atropine, Other Antispasmodics

What Upcoming Trends Are Expected To Impact The Antispasmodics Drugs Market Globally?

Dominating the market for antispasmodic drugs, product innovation has been recognized as a crucial trend. To fortify their standing in the market, leading companies within the antispasmodic drugs industry are capitalizing on the creation of innovative solutions. Ardelyx Inc., an American biopharmaceutical company, unveiled IBSRELA, an NHE-3 inhibitor designed for the treatment of individuals suffering from irritable bowel syndrome with constipation (IBS-C), in April 2022. This revolutionizing product, proven in Phase 3 clinical studies, brings an innovative treatment choice with a unique mode of action, ready to tackle constipation and various abdominal symptoms commonly seen in IBS-C patients.

Who Are The Main Participants Shaping The Antispasmodics Drugs Market Landscape?

Major companies operating in the antispasmodics drugs market include Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/antispasmodics-drugs-global-market-report

Which Region Currently Holds The Largest Share In The Antispasmodics Drugs Market?

North America was the largest region in the antispasmodics drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9414&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model